1604.00
2.33%
Deven Choksey
Tatva Chintan is transitioning into a stronger growth phase primarily driven by SDA recovery, clearer electrolyte-salt commercialization, scalable agro/pharma pipelines, and a structurally high-entry-barrier semiconductor opportunity.
ICICI Securities Limited increased Buy price target of Tatva Chintan Pharma Chem Ltd. to 2385.0 on 20 Oct, 2026.
More from Tatva Chintan Pharma Chem Ltd.
Recommended